Cancer chemotherapy and drug metabolism

Drug Metabolism and Disposition

Volumn 33, Issue 8, 2005, Pages 1083-1096

  Riddick, David S ^a   Lee, Chunja ^a   Ramji, Shairoz ^a   Chinje, Edwin C ^b   Cowen, Rachel L ^b   Williams, Kaye J ^b   Patterson, Adam V ^c   Stratford, Ian J ^b   Morrow, Charles S ^d   Townsend, Alan J ^d   Jounaidi, Youssef ^e   Chen, Chong Sheng ^e   Su, Ting ^e   Lu, Hong ^e   Schwartz, Pamela S ^e   Waxman, David J ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DOXORUBICIN; DRUG METABOLIZING ENZYME; GLUTATHIONE; MITOMYCIN C; TIRAPAZAMINE;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONJUGATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; GENE THERAPY; GENETIC VECTORS; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; LIVER; NEOPLASMS; OXIDATION-REDUCTION; PRODRUGS;

EID: 22944471145     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.004374     Document Type: Conference Paper

References (70)

1. Afsar A, Lee C, and Riddick DS (1996) Modulation of the expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol 74:150-156.
2. Aghi M, Chou TC, Suling K, Breakefield XO, and Chiocca EA (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P4502B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59:3861-3865.
3. Beaumont PO, Moore MJ, Ahmad K, Payne MM, Lee C, and Riddick DS (1998) Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. Cancer Res 58:947-955.
4. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, and Naylor S (2003) Hypoxia-mediated tumor targeting. Gene Ther 10:540-549.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, and Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943.
6. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886.
7. Brown JM and Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447.
8. Chawla A, Repa JJ, Evans RM, and Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science (Wash DC) 294:1866-1870.
9. Chen L and Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405-1416.
10. Cheung RLH, Lee C, Jones EJ, and Riddick DS (1996) Lack of effect of methotrexate on the expression of constitutive hepatic cytochromes P450 in the male rat. Xenobiotica 26:503-514.
11. Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL, and Stratford IJ (2003) Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63:1248-1255.
12. Cowan KH, Batist G, Tulpule A, Sinha BK, and Myers CE (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83:9328-9332.
13. Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, and Williams KJ (2003) Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2:901-909.
14. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FCD, Telfer BA, Wind NS, and Stratford IJ (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64:1396-1402.
15. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, and Harris AL (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3:515-520.
16. Di Re J, Lee C, and Riddick DS (1999) Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol 77:589-597.
17. Fitzsimmons SA, Lewis AD, Riley RJ, and Workman P (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR4233) to DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15:1503-1510.
18. Forkert PG, Lord JA, and Parkinson A (1996) Alterations in expression of CYP1A1 and NADPH-cytochrome P450 reductase during lung tumor development in SWR/J mice. Carcinogenesis 17:127-132.
19. Garner AP, Paine MJI, Rodriguez-Crespo I, Chinje EC, Ortiz de Montellano P, Stratford IJ, Tew DG, and Wolf CR (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 59:1929-1934.
20. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
21. Goeptar AR, Koppele JMT, Lamme EK, Pique JM, and Vermeulen NPE (1993) Cytochrome P450-2B1-mediated one-electron reduction of Adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 44:1267-1277.
22. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, and Naylor S (2000) The macrophage: a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 7:255-262.
23. Hayes JD and Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600.
24. Hihi AK, Michalik L, and Wahli W (2002) PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59:790-798.
25. Holland I, Cole S, Kuchler K, and Higgins C (2003) ABC Proteins From Bacteria to Man. Academic Press, Amsterdam.
26. Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, and Chiocca EA (2001) Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 61:864-868.
27. Ishikawa T (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463-468.
28. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833-4836.
29. Jounaidi Y and Waxman DJ (2000) Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 60:3761-3769.
30. Jounaidi Y and Waxman DJ (2001) Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 61:4437-4444.
31. Jounaidi Y and Waxman DJ (2004) Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 64:292-303.
32. Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, et al. (2001) Direct retroviral delivery of human cytochrome P4502B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 8:473-482.
33. Kivisto KT, Kroemer HK, and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530.
34. 2 metabolite binds peroxisome proliferator-activated receptor-γ and promotes adipocyte differentiation. Cell 83:813-819.
35. Lohr M, Hummel F, Faulmann G, Ringel J, Saller R, Hain J, Gunzburg WH, and Salmons B (2002) Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother Pharmacol 49:S21-S24.
36. Lohr M, Kroger JC, Hoffmeyer A, Freund M, Hain J, Holle A, Knofel WT, Liebe S, Nizze H, Renner M, et al. (2003) Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 1:121-131.
37. Lu H and Waxman DJ (2005) Anti-tumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. Mol Pharmacol 67:1-8.
38. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735.
39. Marchand DJ and Renton KW (1981) Depression of cytochrome P-450-dependent drug biotransformation by Adriamycin. Toxicol Appl Pharmacol 58:83-88.
40. McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, and Robson T (2003) Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther 10:40-48.
41. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, and Varesio LA (1995) A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683-1693.
42. Mimnaugh EG, Trush MA, Ginsburg E, Hirokata Y, and Gram TE (1981) The effects of Adriamycin in vitro and in vivo on hepatic microsomal drug-metabolizing enzymes: role of microsomal lipid peroxidation. Toxicol Appl Pharmacol 61:313-325.
43. Morrow CS, Diah S, Smitherman PK, Schneider E, and Townsend AJ (1998a) Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 19:109-115.
44. Morrow CS, Smitherman PK, Diah K, Schneider E, and Townsend AJ (1998b) Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification: mechanism of GST Al-l- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem 273:20114-20120.
45. Morrow CS, Smitherman PK, and Townsend AJ (2000) Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog 29:170-178.
46. Moscow JA, Morrow CS, and Cowan KH (2003) Drug resistance and its clinical circumvention, in Cancer Medicine, 6th ed (Kufe D, Pollock R, Weischselbaum R, Bast R, Gansler T, Holland J, and Frei E eds) pp 711-725, BC Decker Inc, Hamilton, ON, Canada.
47. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, and Honma Y (2000) Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol 58:27-36.
48. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72:1144-1150.
49. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, and Stratford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76:1338-1347.
50. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, et al. (2002) Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 9:946-954.
51. Paumi CM, Ledford DG, Smitherman PK, Townsend AJ, and Morrow CS (2001) Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance: kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem 276:7952-7956.
52. 2). Biochemistry 43:2345-2352.
53. 2 in MCF7 breast cancer cells. Biochemistry 42:5429-5437.
54. Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, Chiocca EA, and Tanabe KK (2002) Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95:1171-1181.
55. Petros WP and Evans WE (2004) Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol Sci 25:457-464.
56. Ramji S, Lee C, Inaba T, Patterson AV, and Riddick DS (2003) Human NADPH-cytochrome P450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. Cancer Res 63:6914-6919.
57. Rooseboom M, Commandeur JNM, and Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102.
58. Schwartz PS, Chen CS, and Waxman DJ (2002) Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res 62:6928-6937.
59. Schwartz PS and Waxman DJ (2001) Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60:1268-1279.
60. Scudiero DA, Monks A, and Sausville EA (1998) Cell line designation change: multidrugresistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90:862.
61. 2 metabolite generated during inflammatory processes. J Biol Chem 277:10459-10466.
62. Siim BG, Menke DR, Dorie MJ, and Brown JM (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57:2922-2928.
63. Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, and Wilson WR (2004) Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res 64:736-742.
64. Smitherman PK, Townsend AJ, Kute TE, and Morrow CS (2004) Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 308:260-267.
65. Springer CJ and Niculescu-Duvaz I (1996) Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv Drug Deliv Rev 22:351-364.
66. Stratford IJ, Williams KJ, Cowen RL, and Jaffar M (2003) Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 13:42-52.
67. Thomsen LL and Miles DW (1998) Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metastasis Rev 17:107-118.
68. Vaupel P, Thews O, and Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243-259.
69. Wang K, Ramji S, Bhathena A, Lee C, and Riddick DS (1999) Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Xenobiotica 29:155-170.
70. Waxman DJ and Schwartz PS (2003) Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 63:8563-8572.